Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""CARBOPLATIN"" wg kryterium: Temat


Tytuł:
[Dose-dense paclitaxel plus carboplatin in combination with trastuzumab neoadjuvant versus standard adjuvant therapy in human epidermal growth factor receptor-2 positive and hormone receptor negative breast cancer: a prospective cohort study].
Autorzy:
Xiu M; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Lu Y; Department of Medical Oncology, the First People's Hospital of Nanning, Nanning 530016, China.
Wang X; Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Fan Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li Q; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li Q; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang JY; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Luo Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Cai RG; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Chen SS; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yuan P; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Ma F; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Xu BH; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhang P; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Aug 23; Vol. 45 (8), pp. 709-716.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Carboplatin*/therapeutic use
Paclitaxel*/therapeutic use
Triple Negative Breast Neoplasms*/drug therapy
Female ; Humans ; Anthracyclines/therapeutic use ; Antibiotics, Antineoplastic/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant ; Hormones/therapeutic use ; Neoadjuvant Therapy ; Prospective Studies ; Receptor, ErbB-2/metabolism ; Trastuzumab/therapeutic use
Czasopismo naukowe
Tytuł:
Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.
Autorzy:
Gentzler RD; Department of Medicine, Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA.
Mohindra NA; Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Jalal SI; Department of Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Reckamp KL; Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Hall RD; Department of Medicine, Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA.
Hanna NH; Department of Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.
Chae YK; Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Koczywas M; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Helenowski IB; Department of Preventive Medicine, Northwestern University, Chicago, IL, USA.
Patel JD; Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2024 Jan 05; Vol. 29 (1), pp. 47-56.
Typ publikacji:
Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Carcinoma, Squamous Cell*/drug therapy
Adult ; Humans ; Carboplatin/pharmacology ; Carboplatin/therapeutic use ; B7-H1 Antigen ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Paclitaxel
Czasopismo naukowe
Tytuł:
Receptor mediated targeting of EGF-conjugated alginate-PAMAM nanoparticles to lung adenocarcinoma: 2D/3D in vitro and in vivo evaluation.
Autorzy:
Ilhan-Ayisigi E; Department of Genetic and Bioengineering, Faculty of Engineering and Architecture, Kirsehir Ahi Evran University, Kirsehir, Turkey; Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey.
Saglam-Metiner P; Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey; Translational Pulmonary Research Center (EgeSAM), Ege University, Izmir, Turkey.
Sanci E; Center for Drug Research and Pharmacokinetic Applications (ARGEFAR), Ege University, Izmir, Turkey.
Bakan B; Department of Molecular Biology and Genetics, Faculty of Science, Ataturk University, Erzurum, Turkey.
Yildirim Y; Department of Chemistry, Faculty of Science, Ege University, Izmir, Turkey.
Buhur A; Department of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, Turkey.
Yavasoglu A; Department of Histology and Embryology, Faculty of Medicine, Ege University, Izmir, Turkey.
Yavasoglu NUK; Translational Pulmonary Research Center (EgeSAM), Ege University, Izmir, Turkey; Center for Drug Research and Pharmacokinetic Applications (ARGEFAR), Ege University, Izmir, Turkey; Department of Biology, Faculty of Science, Ege University, Izmir, Turkey. Electronic address: .
Yesil-Celiktas O; Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey; Translational Pulmonary Research Center (EgeSAM), Ege University, Izmir, Turkey. Electronic address: .
Pokaż więcej
Źródło:
International journal of biological macromolecules [Int J Biol Macromol] 2024 Mar; Vol. 261 (Pt 1), pp. 129758. Date of Electronic Publication: 2024 Jan 28.
Typ publikacji:
Journal Article
MeSH Terms:
Dendrimers*
Nanoparticles*
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Adenocarcinoma of Lung*/drug therapy
Lung Neoplasms*/drug therapy
Female ; Animals ; Epidermal Growth Factor/metabolism ; Carboplatin ; Alginates ; Cell Line, Tumor ; Drug Delivery Systems
Czasopismo naukowe
Tytuł:
Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization.
Autorzy:
Jimenez-Rodriguez TW; Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII), Fundación Española para la Ciencia y la Tecnología (FECyT), Madrid, Spain.
de Las Vecillas L; Allergy Section, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain.; Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.
Labella M; ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII), Fundación Española para la Ciencia y la Tecnología (FECyT), Madrid, Spain.; Allergy Clinical Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.; Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.
Lynch DM; Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Besz KM; Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Marquis K; Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Burgos A; Pharmacy Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
Soriano Gomis V; Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII), Fundación Española para la Ciencia y la Tecnología (FECyT), Madrid, Spain.; Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain.
Lozano I; Oncology Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
Antón RAM; Oncology Day Hospital Nursing Service, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
de la Calle FM; Immunology Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
González Delgado MP; Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII), Fundación Española para la Ciencia y la Tecnología (FECyT), Madrid, Spain.; Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain.
Gutiérrez A; Allergy Section, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain.
Montenegro E; Allergy Section, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain.
Rodríguez F; Allergy Section, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain.
Fernández Sánchez FJ; Allergy Section, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; ARADyAL Spanish Network (RD16/0006), Instituto de Salud Carlos III (ISCIII), Fundación Española para la Ciencia y la Tecnología (FECyT), Madrid, Spain.; Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain.
Castells M; Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Pokaż więcej
Źródło:
Allergy [Allergy] 2024 Mar; Vol. 79 (3), pp. 679-689. Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/adverse effects
Drug Hypersensitivity*/diagnosis
Drug Hypersensitivity*/etiology
Drug Hypersensitivity*/therapy
Hypersensitivity*
Humans ; Oxaliplatin/adverse effects ; Carboplatin/adverse effects ; Retrospective Studies ; Desensitization, Immunologic/methods ; Cytokines ; Phenotype ; Biomarkers
Czasopismo naukowe
Tytuł:
ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis.
Autorzy:
Gong K; Institute of Reproductive Health and Perinatology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China.; Department of Gynecology and Obstetrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, China.
Huang Y; School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China.
Zheng Y; Department of Gynecology and Obstetrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, China.
Hao W; Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, Guangdong, China. .
Shi K; Institute of Reproductive Health and Perinatology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China. .; Department of Gynecology and Obstetrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Feb 21; Vol. 22 (1), pp. 192. Date of Electronic Publication: 2024 Feb 21.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
Neoplasms, Glandular and Epithelial*
Animals ; Humans ; Female ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/genetics ; Carcinoma, Ovarian Epithelial/metabolism ; Carboplatin/therapeutic use ; Cell Line, Tumor ; Prognosis ; Cell Proliferation ; Gene Expression Regulation, Neoplastic ; Forkhead Transcription Factors/metabolism
Czasopismo naukowe
Tytuł:
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Autorzy:
Galsky MD; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: .
Guan X; Genentech Inc., South San Francisco, CA 94080, USA.
Rishipathak D; Genentech Inc., South San Francisco, CA 94080, USA.
Rapaport AS; Genentech Inc., South San Francisco, CA 94080, USA.
Shehata HM; Genentech Inc., South San Francisco, CA 94080, USA.
Banchereau R; Genentech Inc., South San Francisco, CA 94080, USA.
Yuen K; Genentech Inc., South San Francisco, CA 94080, USA.
Varfolomeev E; Genentech Inc., South San Francisco, CA 94080, USA.
Hu R; Genentech Inc., South San Francisco, CA 94080, USA.
Han CJ; Genentech Inc., South San Francisco, CA 94080, USA.
Li H; Hoffmann-La Roche Ltd, Mississauga, ON, Canada.
Liang Y; Genentech Inc., South San Francisco, CA 94080, USA.
Vucic D; Genentech Inc., South San Francisco, CA 94080, USA.
Wang L; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; GeneDx, Stamford, CT, USA.
Zhu J; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; GeneDx, Stamford, CT, USA.
Yu H; GeneDx, Stamford, CT, USA.
Herbst RH; Immunai, New York, NY, USA.
Hajaj E; Immunai, New York, NY, USA.
Kiner E; Immunai, New York, NY, USA.
Bamias A; National and Kapodistrian University of Athens, Athens, Greece.
De Santis M; Department of Urology, Charité - Universitätsmedizin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.
Davis ID; Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia.
Arranz JÁ; Gregorio Marañón General University Hospital, Madrid, Spain.
Kikuchi E; St. Marianna University School of Medicine, Kawasaki, Japan.
Bernhard S; Roche Products Ltd, Welwyn Garden City, UK.
Williams P; Genentech Inc., South San Francisco, CA 94080, USA.
Lee C; Roche Products Ltd, Welwyn Garden City, UK.
Mellman I; Genentech Inc., South San Francisco, CA 94080, USA.
Sanjabi S; Genentech Inc., South San Francisco, CA 94080, USA.
Johnston R; Genentech Inc., South San Francisco, CA 94080, USA.
Black PC; Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
Grande E; MD Anderson Cancer Center Madrid, Madrid, Spain.
Mariathasan S; Genentech Inc., South San Francisco, CA 94080, USA. Electronic address: .
Pokaż więcej
Źródło:
Cell reports. Medicine [Cell Rep Med] 2024 Feb 20; Vol. 5 (2), pp. 101393. Date of Electronic Publication: 2024 Jan 26.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/chemically induced
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/pathology
Urologic Neoplasms*/drug therapy
Urologic Neoplasms*/chemically induced
Urologic Neoplasms*/pathology
Humans ; Carboplatin/therapeutic use ; Cisplatin/therapeutic use ; Deoxycytidine/therapeutic use ; Gemcitabine
Czasopismo naukowe
Tytuł:
Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial.
Autorzy:
Zhang M; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, 127 Dongming Rd, Zhengzhou, 450003, China.
Zhang G; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, 127 Dongming Rd, Zhengzhou, 450003, China.
Niu Y; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, 127 Dongming Rd, Zhengzhou, 450003, China.
Zhang G; Department of Medical Oncology, Xinxiang Central Hospital, 56 Jinsui Rd, Xinxiang, 453000, China.
Ji Y; Department of Medical Oncology, The First Affiliated Hospital of Xinxiang Medical University, 88 Jiankang Rd, Xinxiang, 453199, China.
Yan X; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, 127 Dongming Rd, Zhengzhou, 450003, China.
Zhang X; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, 127 Dongming Rd, Zhengzhou, 450003, China.
Wang Q; Department of Medical Oncology, The Second People's Hospital of Nanyang, 66 Jianshe Rd, Nanyang, 473000, China.
Jing X; Department of Medical Oncology, The First People's Hospital of Pingdingshan, 117 Youyue Rd, Pingdingshan, 467099, China.
Wang J; Department of Medical Oncology, Anyang Cancer Hospital, 2 N Huanbin Rd, Anyang, 455001, China.
Ma Z; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, 127 Dongming Rd, Zhengzhou, 450003, China.
Wang H; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, 127 Dongming Rd, Zhengzhou, 450003, China. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2024 Feb 19; Vol. 15 (1), pp. 1512. Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:
Clinical Trial, Phase II; Multicenter Study; Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Squamous Cell*/drug therapy
Carcinoma, Squamous Cell*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/therapeutic use ; Carboplatin/adverse effects
Czasopismo naukowe
Tytuł:
Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.
Autorzy:
Aputen AD; School of Science, Western Sydney University, Sydney, NSW 2751, Australia.
Elias MG; School of Science, Western Sydney University, Sydney, NSW 2751, Australia.; Ingham Institute, Sydney, NSW 2170, Australia.
Gilbert J; Calvary Mater Newcastle Hospital, Newcastle, NSW 2298, Australia.
Sakoff JA; Calvary Mater Newcastle Hospital, Newcastle, NSW 2298, Australia.
Gordon CP; School of Science, Western Sydney University, Sydney, NSW 2751, Australia.
Scott KF; Ingham Institute, Sydney, NSW 2170, Australia.; School of Medicine, Western Sydney University, Sydney, NSW 2751, Australia.
Aldrich-Wright JR; School of Science, Western Sydney University, Sydney, NSW 2751, Australia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 11; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 11.
Typ publikacji:
Journal Article
MeSH Terms:
Prodrugs*/chemistry
Antineoplastic Agents*/chemistry
Hydroxyindoleacetic Acid/*analogs & derivatives
Humans ; Cisplatin/pharmacology ; Platinum/chemistry ; Oxaliplatin/pharmacology ; Carboplatin/pharmacology ; Carboplatin/chemistry ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck.
Autorzy:
Humphries A; Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.
Zhou CJ; School of Medicine, University of California San Francisco, San Francisco, California, USA.
Welsh M; Stanford Cancer Institute, Palo Alto, California, USA.
Lem M; Department of Plastic and Reconstructive Surgery, University of California San Francisco, San Francisco, California, USA.
Kang H; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Algazi AP; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Pokaż więcej
Źródło:
Head & neck [Head Neck] 2024 Feb; Vol. 46 (2), pp. 321-327. Date of Electronic Publication: 2023 Nov 23.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Squamous Cell*/drug therapy
Carcinoma, Squamous Cell*/etiology
Head and Neck Neoplasms*/drug therapy
Head and Neck Neoplasms*/etiology
Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/etiology ; Carboplatin ; Paclitaxel ; B7-H1 Antigen ; Retrospective Studies ; Neoplasm Recurrence, Local/pathology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma.
Autorzy:
Ikoma Y; Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Nakamura N; Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Kitagawa J; Department of Hematology, Gifu Municipal Hospital, Gifu, Japan.
Miwa T; Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Takada E; Department of Hematology, Gifu-Seino Medical Center, Gihoku Kosei Hospital, Gifu, Japan.
Matsumoto T; Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Shibata Y; Department of Hematology, Gifu Municipal Hospital, Gifu, Japan.
Nakamura H; Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Kanemura N; Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.; Department of Hematology, Chuno Kosei Hospital, Gifu, Japan.
Kasahara S; Department of Hematology, Gifu Municipal Hospital, Gifu, Japan.; Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu, Japan.
Hara T; Department of Hematology, Matsunami General Hospital, Gifu, Japan.
Sawada M; Department of Hematology, Gifu Red Cross Hospital, Gifu, Japan.
Tsurumi H; Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.; Department of Hematology, Matsunami General Hospital, Gifu, Japan.
Shimizu M; Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Jan; Vol. 42 (1), pp. e3236. Date of Electronic Publication: 2023 Nov 06.
Typ publikacji:
Clinical Trial, Phase II; Multicenter Study; Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/methods
Lymphoma, Non-Hodgkin*/drug therapy
Humans ; Aged ; Rituximab/adverse effects ; Gemcitabine ; Carboplatin/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Neoplasm Recurrence, Local/pathology ; Transplantation, Autologous ; Dexamethasone/adverse effects ; Salvage Therapy/methods
Czasopismo naukowe
Tytuł:
A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
Autorzy:
Nakamichi S; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
Kubota K; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan. Electronic address: .
Matsuyama K; Department of Health Policy and Management, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
Misumi T; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama-shi, Kanagawa, Japan.
Kozuki T; Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan.
Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai-shi, Miyagi, Japan.
Naoki K; Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara-shi, Kanagawa, Japan.
Kobayashi N; Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
Shukuya T; Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.
Shimokawa T; Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Ishihara M; Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
Wakui H; Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Hosomi Y; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Bunkyo-ku, Tokyo, Japan.
Tanaka H; Department of Internal Medicine, Niigata Cancer Center Hospital, Chuo-ku, Niigata, Japan.
Saito H; Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Hosokawa S; Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama-shi, Okayama, Japan.
Takiguchi Y; Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kasai T; Division of Thoracic Oncology, Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya-shi, Tochigi, Japan.
Nokihara H; Respiratory Medicine, Center Hospital of the National Center for Global Health and Medicine, Hiroshima, Japan.
Morita R; Department of Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan.
Aono H; Department of Respiratory Medicine, Tokyo Metropolitan Police Hospital, Nakano-ku, Tokyo, Japan.
Furuya N; Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki-shi, Kanagawa, Japan.
Okamoto H; Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Pokaż więcej
Źródło:
Clinical lung cancer [Clin Lung Cancer] 2024 Jan; Vol. 25 (1), pp. 85-90. Date of Electronic Publication: 2023 Oct 04.
Typ publikacji:
Clinical Trial, Phase II; Multicenter Study; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Carcinoma, Squamous Cell*/drug therapy
Antibodies, Monoclonal, Humanized*
Leucine/*analogs & derivatives
Humans ; Carboplatin ; Prospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Paclitaxel ; Albumins
Czasopismo naukowe
Tytuł:
Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
Autorzy:
Ueki Y; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-Dori, Chuo-Ku, Niigata City, Niigata, 950-8510, Japan. .
Ohshima S; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-Dori, Chuo-Ku, Niigata City, Niigata, 950-8510, Japan.
Yokoyama Y; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-Dori, Chuo-Ku, Niigata City, Niigata, 950-8510, Japan.
Takahashi T; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-Dori, Chuo-Ku, Niigata City, Niigata, 950-8510, Japan.
Shodo R; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-Dori, Chuo-Ku, Niigata City, Niigata, 950-8510, Japan.
Yamazaki K; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-Dori, Chuo-Ku, Niigata City, Niigata, 950-8510, Japan.
Ohtaki K; Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata City, Niigata, Japan.
Saijo K; Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata City, Niigata, Japan.
Tanaka R; Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata City, Niigata, Japan.
Togashi T; Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata City, Niigata, Japan.
Sato Y; Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata City, Niigata, Japan.
Takano S; Department of Otorhinolaryngology, Nagaoka Red Cross Hospital, Nagaoka City, Niigata, Japan.
Omata J; Department of Otorhinolaryngology, Nagaoka Red Cross Hospital, Nagaoka City, Niigata, Japan.
Takahashi N; Department of Otorhinolaryngology, Nagaoka Red Cross Hospital, Nagaoka City, Niigata, Japan.
Okabe R; Department of Otorhinolaryngology, Nagaoka Red Cross Hospital, Nagaoka City, Niigata, Japan.
Horii A; Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-Dori, Chuo-Ku, Niigata City, Niigata, 950-8510, Japan.
Pokaż więcej
Źródło:
International journal of clinical oncology [Int J Clin Oncol] 2024 Jan; Vol. 29 (1), pp. 20-26. Date of Electronic Publication: 2023 Oct 16.
Typ publikacji:
Clinical Trial, Phase II; Multicenter Study; Journal Article
MeSH Terms:
Head and Neck Neoplasms*/drug therapy
Head and Neck Neoplasms*/radiotherapy
Carcinoma, Squamous Cell*/drug therapy
Carcinoma, Squamous Cell*/radiotherapy
Adult ; Male ; Humans ; Aged ; Female ; Cisplatin ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Carboplatin ; Prospective Studies ; Chemoradiotherapy ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Patients with Non-Small-Cell Lung Cancer.
Autorzy:
Wang, Chen-Yu (AUTHOR)
Dai, Hao-Ran (AUTHOR)
Tan, Yu-Ping (AUTHOR)
Yang, Di-Hong (AUTHOR)
Niu, Xiao-Min (AUTHOR)
Han, Lu (AUTHOR)
Wang, Wen (AUTHOR)
Ma, Ling-Ling (AUTHOR)
Julku, Aleksi (AUTHOR)
Jiao, Zheng (AUTHOR)
Pokaż więcej
Źródło:
Pharmaceuticals (14248247). Feb2024, Vol. 17 Issue 2, p238. 12p.
Czasopismo naukowe
Tytuł:
Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
Autorzy:
Sharma P; Department of Biotechnology, Thapar Institute of Engineering & Technology, Patiala, Punjab, India.
Singh N; Department of Pulmonary Medicine, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Sharma S; Department of Biotechnology, Thapar Institute of Engineering & Technology, Patiala, Punjab, India.
Pokaż więcej
Źródło:
Journal of biochemical and molecular toxicology [J Biochem Mol Toxicol] 2023 Mar; Vol. 37 (3), pp. e23269. Date of Electronic Publication: 2022 Dec 11.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
ATP-Binding Cassette Transporters*/genetics
Carboplatin*/administration & dosage
Carboplatin*/adverse effects
Cisplatin*/administration & dosage
Cisplatin*/adverse effects
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
South Asian People*/genetics
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Anemia/chemically induced ; Anemia/genetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Chemical and Drug Induced Liver Injury/etiology ; Chemical and Drug Induced Liver Injury/genetics ; Diarrhea/chemically induced ; Diarrhea/genetics ; Docetaxel/administration & dosage ; Docetaxel/adverse effects ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Gefitinib/administration & dosage ; Gefitinib/adverse effects ; Gemcitabine/administration & dosage ; Gemcitabine/adverse effects ; Genotype ; India ; Irinotecan/administration & dosage ; Irinotecan/adverse effects ; Kidney Diseases/chemically induced ; Kidney Diseases/genetics ; Leukopenia/chemically induced ; Leukopenia/genetics ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Pemetrexed/administration & dosage ; Pemetrexed/adverse effects ; Polymorphism, Genetic ; Small Cell Lung Carcinoma/drug therapy ; Small Cell Lung Carcinoma/genetics ; Small Cell Lung Carcinoma/pathology
Czasopismo naukowe
Tytuł:
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
Autorzy:
Nabet BY; Genentech Inc., South San Francisco CA, USA. Electronic address: .
Hamidi H; Genentech Inc., South San Francisco CA, USA.
Lee MC; Genentech Inc., South San Francisco CA, USA.
Banchereau R; Genentech Inc., South San Francisco CA, USA.
Morris S; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Adler L; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Gayevskiy V; Genentech Inc., South San Francisco CA, USA; Rancho Biosciences, San Diego, CA, USA.
Elhossiny AM; Genentech Inc., South San Francisco CA, USA.
Srivastava MK; Genentech Inc., South San Francisco CA, USA.
Patil NS; Genentech Inc., South San Francisco CA, USA.
Smith KA; Genentech Inc., South San Francisco CA, USA.
Jesudason R; Genentech Inc., South San Francisco CA, USA.
Chan C; Genentech Inc., South San Francisco CA, USA.
Chang PS; Genentech Inc., South San Francisco CA, USA.
Fernandez M; Genentech Inc., South San Francisco CA, USA.
Rost S; Genentech Inc., South San Francisco CA, USA.
McGinnis LM; Genentech Inc., South San Francisco CA, USA.
Koeppen H; Genentech Inc., South San Francisco CA, USA.
Gay CM; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Minna JD; Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX 75390-8593, USA; Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA; Departments of Internal Medicine and Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Heymach JV; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chan JM; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA.
Rudin CM; Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; Weill Cornell Medical College, New York, NY 10065, USA.
Byers LA; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Liu SV; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Reck M; Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany.
Shames DS; Genentech Inc., South San Francisco CA, USA. Electronic address: .
Pokaż więcej
Źródło:
Cancer cell [Cancer Cell] 2024 Mar 11; Vol. 42 (3), pp. 429-443.e4. Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/genetics
Small Cell Lung Carcinoma*/genetics
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Carboplatin/therapeutic use ; Etoposide/therapeutic use ; Immunotherapy
Czasopismo naukowe
Tytuł:
Mesonephric-like adenocarcinoma of the ovary.
Autorzy:
Yang Y; Dalian Medical University, Dalian, 116000, PR China.
Zhao M; Dalian Medical University, Dalian, 116000, PR China.
Jia Q; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Tang H; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Xing T; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Li Y; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Tang B; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Xu L; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Wei W; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Zheng H; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Shi R; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China.
Xia B; Department of Gynecological Oncology, Division of Life Sciences and Medicine, the First Affiliated Hospital of University of Science and Technology of China, University of Science and Technology of China, Hefei, 230031, PR China. .
Chen J; Department of Gynecology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, 213003, PR China. .
Pokaż więcej
Źródło:
Journal of ovarian research [J Ovarian Res] 2024 Mar 05; Vol. 17 (1), pp. 57. Date of Electronic Publication: 2024 Mar 05.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Ovarian Neoplasms*/diagnosis
Ovarian Neoplasms*/therapy
Adenocarcinoma*/diagnosis
Adenocarcinoma*/therapy
Female ; Humans ; Middle Aged ; Pelvis ; Carboplatin
Czasopismo naukowe
Tytuł:
Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.
Autorzy:
Chao L; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Liu J; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Chen Y; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Fan Y; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Guo S; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Zhang S; Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Mar; Vol. 15 (8), pp. 622-629. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Esophageal Squamous Cell Carcinoma*/drug therapy
Esophageal Squamous Cell Carcinoma*/surgery
Esophageal Neoplasms*/drug therapy
Esophageal Neoplasms*/surgery
Esophageal Neoplasms*/pathology
Antibodies, Monoclonal, Humanized*
Humans ; Carboplatin/therapeutic use ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Retrospective Studies ; Induction Chemotherapy ; Neoadjuvant Therapy ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Albumins/therapeutic use
Czasopismo naukowe
Tytuł:
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial.
Autorzy:
Diéras V; Medical Oncology Department, Institut Curie, 26 rue d'Ulm, 75005, Paris, France; Medical Oncology Department, Centre Eugène Marquis, Av. de la Bataille Flandres-Dunkerque CS 44229, 35000 Rennes, France. Electronic address: .
Han HS; Moffitt Cancer Center, 12920 McKinley Drive, Tampa, FL 33612, USA.
Wildiers H; Department of General Medical Oncology, University Hospitals Leuven, Herestraat 49, O&N4 box 818, 3000 Leuven, Belgium.
Friedlander M; School of Clinical Medicine, UNSW Sydney, Cnr High St & Botany St., Sydney NSW 2052, Australia; Department of Medical Oncology, The Prince of Wales Hospital, Barker Street, Randwick, NSW 2031 Australia.
Ayoub JP; Centre Hospitalier de l'Université de Montréal, 1000 rue Saint-Denis, Montréal, QC H2X 0C1, Canada.
Puhalla SL; UPMC Hillman Cancer Center, 9100 Babcock Blvd Ste G600, Pittsburgh, PA 15237, USA.
Loirat D; Medical Oncology Department, Institut Curie, 26 rue d'Ulm, 75005, Paris, France.
Ratajczak C; AbbVie, 1 N Waukegan Rd, North Chicago, IL 60044, USA.
Adamu H; AbbVie, 1 N Waukegan Rd, North Chicago, IL 60044, USA.
Girardi V; AbbVie, 1 N Waukegan Rd, North Chicago, IL 60044, USA.
Arun BK; The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX 77030, USA.
Pokaż więcej
Źródło:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Mar; Vol. 200, pp. 113580. Date of Electronic Publication: 2024 Jan 28.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Benzimidazoles*
Humans ; Female ; Carboplatin ; Paclitaxel ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
SCR Disease Name:
Breast Cancer, Familial
Czasopismo naukowe
Tytuł:
Treatment of node-positive endometrial cancer: chemotherapy, radiation, immunotherapy, and targeted therapy.
Autorzy:
Tubridy EA; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA. .
Taunk NK; Department of Radiation Oncology, Perelman Center for Advanced Medicine, Philadelphia, PA, 19104, USA.
Ko EM; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, USA.; Leonard Davis Institute of Health Economics, University of Pennsylvania Health Systems, Philadelphia, PA, USA.; Penn Center for Cancer Care Innovation, Abramson Cancer Center, University of Pennsylvania Health Systems, Philadelphia, PA, USA.
Pokaż więcej
Źródło:
Current treatment options in oncology [Curr Treat Options Oncol] 2024 Mar; Vol. 25 (3), pp. 330-345. Date of Electronic Publication: 2024 Jan 04.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Endometrial Neoplasms*/drug therapy
Brachytherapy*
Female ; Humans ; Neoplasm Staging ; Carboplatin/therapeutic use ; Chemotherapy, Adjuvant ; Immunotherapy ; Radiotherapy, Adjuvant ; Retrospective Studies ; Neoplasm Recurrence, Local/pathology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies